CHRISTIAN AZODE: Open Payments
NPI 1306492046 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$574 in 15 payments from 7 companies in 2025. Trend: 2023 $192 · 2024 $339 · 2025 $574
Food & beverage: $574
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 5 | $194 |
| Biogen, Inc. | 2 | $122 |
| E.R. Squibb & Sons, L.L.C. | 2 | $107 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 1 | $46 |
| Gilead Sciences, Inc. | 1 | $23 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
Products named: FANAPT, ZURZUVAE, COBENFY, CAPLYTA, REXULTI, INGREZZA.
Industry payments across AZ — which companies pay providers there.
